Urticaria: Diagnostic and Treatment Considerations
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Photoaging & Skin Damage
Use_for_Revised_OFC_Only_2006_PhotoagingSkinDamage 5/21/13 9:11 AM Page 2 PEORIA (309) 674-7546 MORTON (309) 263-7546 GALESBURG (309) 344-5777 PERU (815) 224-7400 NORMAL (309) 268-9980 CLINTON, IA (563) 242-3571 DAVENPORT, IA (563) 344-7546 SoderstromSkinInstitute.comsoderstromskininstitute.com FROMFrom YOUR Your DERMATOLOGISTDermatologist [email protected]@skinnews.com PHOTOAGING & SKIN DAMAGE Before You Worship The Sun Who’s At Risk? Today, many researchers and dermatologists Skin types that burn easily and tan rarely are believe that wrinkling and aging changes of the skin much more susceptible to the ravages of the sun on the are much more related to sun damage than to age! skin than are those that tan easily, rather than burn. Many of the signs of skin damage from the sun are Light complected, blue-eyed, red-haired people such as pictured on these pages. The decrease in the ozone Swedish, Irish, and English, are usually more suscep- layer, increasing the sun’s intensity, and the increasing tible to photo damage, and their skin shows the signs sun exposure among our population – through work, of photo damage earlier in life and in a more pro- sports, sunbathing and tanning parlors – have taken a nounced manner. Dark complexions give more protec- tremendous toll on our skin. Sun damage to the skin tion from light and the sun. ranks with other serious health dangers of smoking, alcohol, and increased cholesterol, and is being seen in younger and younger people. NO TAN IS A SAFE TAN! Table of Contents Sun Damage .............................................Pg. 1 Skin Cancer..........................................Pgs. 2-3 Mohs Micrographic Surgery ......................Pg. -
3628-3641-Pruritus in Selected Dermatoses
Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2016; 20: 3628-3641 Pruritus in selected dermatoses K. OLEK-HRAB 1, M. HRAB 2, J. SZYFTER-HARRIS 1, Z. ADAMSKI 1 1Department of Dermatology, University of Medical Sciences, Poznan, Poland 2Department of Urology, University of Medical Sciences, Poznan, Poland Abstract. – Pruritus is a natural defence mech - logical self-defence mechanism similar to other anism of the body and creates the scratch reflex skin sensations, such as touch, pain, vibration, as a defensive reaction to potentially dangerous cold or heat, enabling the protection of the skin environmental factors. Together with pain, pruritus from external factors. Pruritus is a frequent is a type of superficial sensory experience. Pruri - symptom associated with dermatoses and various tus is a symptom often experienced both in 1 healthy subjects and in those who have symptoms systemic diseases . Acute pruritus often develops of a disease. In dermatology, pruritus is a frequent simultaneously with urticarial symptoms or as an symptom associated with a number of dermatoses acute undesirable reaction to drugs. The treat - and is sometimes an auxiliary factor in the diag - ment of this form of pruritus is much easier. nostic process. Apart from histamine, the most The chronic pruritus that often develops in pa - popular pruritus mediators include tryptase, en - tients with cholestasis, kidney diseases or skin dothelins, substance P, bradykinin, prostaglandins diseases (e.g. atopic dermatitis) is often more dif - and acetylcholine. The group of atopic diseases is 2,3 characterized by the presence of very persistent ficult to treat . Persistent rubbing, scratching or pruritus. -
Genital Lichen Simplex Chronicus (Eczema, Neurodermatitis, Dermatitis) !
Libby Edwards, MD Genital Lichen Simplex Chronicus (eczema, neurodermatitis, dermatitis) ! Lichen simplex chronicus (LSC), or eczema, is a common skin condition that is very itchy. Although not dangerous in any way, both the itching, and the pain from rubbing and scratching, can be miserable. Eczema/LSC of the genital area most often affects the scrotum of men, the vulva of women, or the rectal skin of both. Many people with eczema/LSC have had sensitive skin or eczema/LSC on other areas of the skin at some point, and many have a tendency towards allergies, especially hay fever or asthma. ! The skin usually appears red or dark, and thick from rubbing and scratching, sometimes with sores from scratching. ! The cause of eczema/LSC is not entirely clear. However, eczema/LSC starts with irritation that triggers itching. Often, at the office visit with the health care provider, the original infection or other initial cause of irritation is no longer present. Common triggers include a yeast or fungus infection, an irritating medication, moisturizer or lubricant, a wet bathing suit, anxiety or depression, over-washing, panty liners, sweat, heat, urine, a contraceptive jelly, an irritating condom, or any other activity or substance that can irritate the skin and start the itching. ! Although rubbing and scratching often feel good at first, rubbing irritates the skin and ultimately makes itching even worse, so that there is more scratching, then more itching, then more scratching. This is called the “itch-scratch cycle.” Treatment is very effective and requires clearing any infection and avoiding irritants as well as using a strong cortisone. -
61497191.Pdf
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Repositório Institucional dos Hospitais da Universidade de Coimbra Metadata of the chapter that will be visualized online Chapter Title Phototoxic Dermatitis Copyright Year 2011 Copyright Holder Springer-Verlag Berlin Heidelberg Corresponding Author Family Name Gonçalo Particle Given Name Margarida Suffix Division/Department Clinic of Dermatology, Coimbra University Hospital Organization/University University of Coimbra Street Praceta Mota Pinto Postcode P-3000-175 City Coimbra Country Portugal Phone 351.239.400420 Fax 351.239.400490 Email [email protected] Abstract • Phototoxic dermatitis from exogenous chemicals can be polymorphic. • It is not always easy to distinguish phototoxicity from photoallergy. • Phytophotodermatitis from plants containing furocoumarins is one of the main causes of phototoxic contact dermatitis. • Topical and systemic drugs are a frequent cause of photosensitivity, often with phototoxic aspects. • The main clinical pattern of acute phototoxicity is an exaggerated sunburn. • Subacute phototoxicity from systemic drugs can present as pseudoporphyria, photoonycholysis, and dyschromia. • Exposure to phototoxic drugs can enhance skin carcinogenesis. Comp. by: GDurga Stage: Proof Chapter No.: 18 Title Name: TbOSD Page Number: 0 Date:1/11/11 Time:12:55:42 1 18 Phototoxic Dermatitis 2 Margarida Gonc¸alo Au1 3 Clinic of Dermatology, Coimbra University Hospital, University of Coimbra, Coimbra, Portugal 4 Core Messages photoallergy, both photoallergic contact dermatitis and 45 5 ● Phototoxic dermatitis from exogenous chemicals can systemic photoallergy, and autoimmunity with photosen- 46 6 be polymorphic. sitivity, as in drug-induced photosensitive lupus 47 7 ● It is not always easy to distinguish phototoxicity from erythematosus in Ro-positive patients taking terbinafine, 48 8 photoallergy. -
ZANTAC® 150 (Ranitidine Hydrochloride) Tablets, USP
PRESCRIBING INFORMATION ZANTAC® 150 (ranitidine hydrochloride) Tablets, USP ZANTAC® 300 (ranitidine hydrochloride) Tablets, USP ZANTAC® 25 (ranitidine hydrochloride effervescent) ® EFFERdose Tablets ® ZANTAC (ranitidine hydrochloride) Syrup, USP DESCRIPTION The active ingredient in ZANTAC 150 Tablets, ZANTAC 300 Tablets, ZANTAC 25 EFFERdose Tablets, and ZANTAC Syrup is ranitidine hydrochloride (HCl), USP, a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2 furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-1,1-ethenediamine, HCl. It has the following structure: The empirical formula is C13H22N4O3S•HCl, representing a molecular weight of 350.87. Ranitidine HCl is a white to pale yellow, granular substance that is soluble in water. It has a slightly bitter taste and sulfurlike odor. Each ZANTAC 150 Tablet for oral administration contains 168 mg of ranitidine HCl equivalent to 150 mg of ranitidine. Each tablet also contains the inactive ingredients FD&C Yellow No. 6 Aluminum Lake, hypromellose, magnesium stearate, microcrystalline cellulose, titanium dioxide, triacetin, and yellow iron oxide. Each ZANTAC 300 Tablet for oral administration contains 336 mg of ranitidine HCl equivalent to 300 mg of ranitidine. Each tablet also contains the inactive ingredients croscarmellose sodium, D&C Yellow No. 10 Aluminum Lake, hypromellose, magnesium stearate, microcrystalline cellulose, titanium dioxide, and triacetin. 1 ZANTAC 25 EFFERdose Tablets for oral administration is an effervescent formulation of ranitidine that must be dissolved in water before use. Each individual tablet contains 28 mg of ranitidine HCl equivalent to 25 mg of ranitidine and the following inactive ingredients: aspartame, monosodium citrate anhydrous, povidone, and sodium bicarbonate. Each tablet also contains sodium benzoate. -
2D6 Substrates 2D6 Inhibitors 2D6 Inducers
Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride -
Urticaria - Primary Care Treatment Pathway
DORSET MEDICINES ADVISORY GROUP Urticaria - Primary Care Treatment Pathway Urticaria – also known as hives or nettle rash – is a raised, itchy rash that can occur on just one part of the body or be spread across large areas. The weals of urticaria last less than 24 hours although patients may develop new weals on a daily basis. If urticaria clears completely within six weeks, it is known as acute urticaria. Urticaria occurring for more than six weeks is referred to as chronic urticaria. Most cases of chronic disease occur without an obvious trigger (chronic spontaneous urticaria). Some urticaria has a physical trigger such as pressure (symptomatic dermographism or delayed pressure urticaria), cold or exercise (cholinergic urticaria), or may be drug induced (e.g. by NSAIDS, ACE inhibitors and opioids). All forms of urticaria can be treated with antihistamine although physical urticaria is less likely to respond to treatment than spontaneous urticaria. Most cases of urticaria settle spontaneously within two years but the condition can last for decades in some patients. Referral criteria Refer routinely to dermatology if patients are not responding to standard treatment (see primary care treatment below, up to step 4), they can then be considered for immunomodulation treatment such as ciclosporin (can be very useful for patients thought to have an autoimmune basis for their urticaria), methotrexate or omalizumab. The diagnosis of urticaria is primarily clinical therefore do not routinely refer for allergy testing. The British Association of Dermatologists (BAD) has produced a patient information leaflet which covers this in detail for patients. PRIOR TO SPECIALIST REFERRAL -conduct a full blood count (FBC), erythrocyte sedimentation rate (ESR), thyroid function tests (TFTs), liver function tests (LFTs), and Helicobacter pylori screening (if gastrointestinal symptoms are present). -
Lichen Simplex Chronicus
LICHEN SIMPLEX CHRONICUS http://www.aocd.org Lichen simplex chronicus is a localized form of lichenified (thickened, inflamed) atopic dermatitis or eczema that occurs in well defined plaques. It is the result of ongoing, chronic rubbing and scratching of the skin in localized areas. It is generally seen in patients greater than 20 years of age and is more frequent in women. Emotional stress can play a part in the course of this skin disease. There is mainly one symptom: itching. The rubbing and scratching that occurs in response to the itch can become automatic and even unconscious making it very difficult to treat. It can be magnified by seeming innocuous stimuli such as putting on clothes, or clothes rubbing the skin which makes the skin warmer resulting in increased itch sensation. The lesions themselves are generally very well defined areas of thickened, erythematous, raised area of skin. Frequently they are linear, oval or round in shape. Sites of predilection include the back of the neck, ankles, lower legs, upper thighs, forearms and the genital areas. They can be single lesions or multiple. This can be a very difficult condition to treat much less resolve. It is of utmost importance that the scratching and rubbing of the skin must stop. Treatment is usually initiated with topical corticosteroids for larger areas and intralesional steroids might also be considered for small lesion(s). If the patient simply cannot keep from rubbing the area an occlusive dressing might be considered to keep the skin protected from probing fingers. Since this is not a histamine driven itch phenomena oral antihistamines are generally of little use in these cases. -
Receptor Antagonist (H RA) Shortages | May 25, 2020 2 2 2 GERD4,5 • Take This Opportunity to Determine If Continued Treatment Is Necessary
H2-receptor antagonist (H2RA) Shortages Background . 2 H2RA Alternatives . 2 Therapeutic Alternatives . 2 Adults . 2 GERD . 3 PUD . 3 Pediatrics . 3 GERD . 3 PUD . 4 Tables Table 1: Health Canada–Approved Indications of H2RAs . 2 Table 2: Oral Adult Doses of H2RAs and PPIs for GERD . 4 Table 3: Oral Adult Doses of H2RAs and PPIs for PUD . 5 Table 4: Oral Pediatric Doses of H2RAs and PPIs for GERD . 6 Table 5: Oral Pediatric Doses of H2RAs and PPIs for PUD . 7 References . 8 H2-receptor antagonist (H2RA) Shortages | May 25, 2020 1 H2-receptor antagonist (H2RA) Shortages BACKGROUND Health Canada recalls1 and manufacturer supply disruptions may be causing shortages of commonly used acid-reducing medications called histamine H2-receptor antagonists (H2RAs) . H2RAs include cimetidine, famotidine, nizatidine and ranitidine . 2 There are several Health Canada–approved indications of H2RAs (see Table 1); this document addresses the most common: gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) . 2 TABLE 1: HEALTH CANADA–APPROVED INDICATIONS OF H2RAs H -Receptor Antagonists (H RAs) Health Canada–Approved Indications 2 2 Cimetidine Famotidine Nizatidine Ranitidine Duodenal ulcer, treatment ü ü ü ü Duodenal ulcer, prophylaxis — ü ü ü Benign gastric ulcer, treatment ü ü ü ü Gastric ulcer, prophylaxis — — — ü GERD, treatment ü ü ü ü GERD, maintenance of remission — ü — — Gastric hypersecretion,* treatment ü ü — ü Self-medication of acid indigestion, treatment and prophylaxis — ü† — ü† Acid aspiration syndrome, prophylaxis — — — ü Hemorrhage from stress ulceration or recurrent bleeding, — — — ü prophylaxis ü = Health Canada–approved indication; GERD = gastroesophageal reflux disease *For example, Zollinger-Ellison syndrome . -
Urticaria from Wikipedia, the Free Encyclopedia Jump To: Navigation, Search "Hives" Redirects Here
Urticaria From Wikipedia, the free encyclopedia Jump to: navigation, search "Hives" redirects here. For other uses, see Hive. Urticaria Classification and external resourcesICD-10L50.ICD- 9708DiseasesDB13606MedlinePlus000845eMedicineemerg/628 MeSHD014581Urtic aria (or hives) is a skin condition, commonly caused by an allergic reaction, that is characterized by raised red skin wheals (welts). It is also known as nettle rash or uredo. Wheals from urticaria can appear anywhere on the body, including the face, lips, tongue, throat, and ears. The wheals may vary in size from about 5 mm (0.2 inches) in diameter to the size of a dinner plate; they typically itch severely, sting, or burn, and often have a pale border. Urticaria is generally caused by direct contact with an allergenic substance, or an immune response to food or some other allergen, but can also appear for other reasons, notably emotional stress. The rash can be triggered by quite innocent events, such as mere rubbing or exposure to cold. Contents [hide] * 1 Pathophysiology * 2 Differential diagnosis * 3 Types * 4 Related conditions * 5 Treatment and management o 5.1 Histamine antagonists o 5.2 Other o 5.3 Dietary * 6 See also * 7 References * 8 External links [edit] Pathophysiology Allergic urticaria on the shin induced by an antibiotic The skin lesions of urticarial disease are caused by an inflammatory reaction in the skin, causing leakage of capillaries in the dermis, and resulting in an edema which persists until the interstitial fluid is absorbed into the surrounding cells. Urticarial disease is thought to be caused by the release of histamine and other mediators of inflammation (cytokines) from cells in the skin. -
Decreased Prevalence of Atopy in Paediatric Patients with Familial
187 EXTENDED REPORT Ann Rheum Dis: first published as 10.1136/ard.2003.007013 on 13 January 2004. Downloaded from Decreased prevalence of atopy in paediatric patients with familial Mediterranean fever C Sackesen, A Bakkaloglu, B E Sekerel, F Ozaltin, N Besbas, E Yilmaz, G Adalioglu, S Ozen ............................................................................................................................... Ann Rheum Dis 2004;63:187–190. doi: 10.1136/ard.2003.007013 Background: A number of inflammatory diseases, including familial Mediterranean fever (FMF), have been shown to be driven by a strongly dominated Th1 response, whereas the pathogenesis of atopic diseases is associated with a Th2 response. Objective: Because dominance of interferon gamma has the potential of inhibiting Th2 type responses— that is, development of allergic disorders, to investigate whether FMF, or mutations of the MEFV gene, See end of article for have an effect on allergic diseases and atopy that are associated with an increased Th2 activity. authors’ affiliations Method: Sixty children with FMF were questioned about allergic diseases such as asthma, allergic rhinitis, ....................... and atopic dermatitis, as were first degree relatives, using the ISAAC Study phase II questionnaire. The Correspondence to: ISAAC Study phase II was performed in a similar ethnic group recruited from central Anatolia among Dr S Ozen, Hacettepe 3041 children. The same skin prick test panel used for the ISAAC Study was used to investigate the University Medical Faculty, presence of atopy in patients with FMF and included common allergens. Paediatric Nephrology Results: The prevalences of doctor diagnosed asthma, allergic rhinitis, and eczema were 3.3, 1.7, and and Rheumatic Diseases Unit, Sihhiye, 06100 3.3%, respectively, in children with FMF, whereas the corresponding prevalences in the ISAAC study were Ankara, Turkey; 6.9, 8.2, and 2.2%, respectively. -
Etiology, Classification, and Treatment of Urticaria
CONTINUING MEDICAL EDUCATION Etiology, Classification, and Treatment of Urticaria Kjetil Kristoffer Guldbakke, MD; Amor Khachemoune, MD, CWS GOAL To understand urticaria to better manage patients with the condition OBJECTIVES Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Discuss the clinical classification of urticaria. 2. Recognize how to diagnose urticaria. 3. Identify treatment options. CME Test on page 50. This article has been peer reviewed and approved Einstein College of Medicine is accredited by by Michael Fisher, MD, Professor of Medicine, the ACCME to provide continuing medical edu- Albert Einstein College of Medicine. Review date: cation for physicians. December 2006. Albert Einstein College of Medicine designates This activity has been planned and imple- this educational activity for a maximum of 1 AMA mented in accordance with the Essential Areas PRA Category 1 CreditTM. Physicians should only and Policies of the Accreditation Council for claim credit commensurate with the extent of their Continuing Medical Education through the participation in the activity. joint sponsorship of Albert Einstein College of This activity has been planned and produced in Medicine and Quadrant HealthCom, Inc. Albert accordance with ACCME Essentials. Drs. Guldbakke and Khachemoune report no conflict of interest. The authors discuss off-label use of colchi- cine, cyclophosphamide, cyclosporine, dapsone, intravenous immunoglobulin, methotrexate, montelukast sodium, nifedipine, plasmapheresis, rofecoxib, sulfasalazine, tacrolimus, thyroxine, and zafirlukast. Dr. Fisher reports no conflict of interest. Urticaria is among the most common skin dis- autoimmune mechanisms are now recognized as a eases. It can be acute, chronic, mediated by a cause of chronic urticaria. A search of the PubMed physical stimulus, or related to contact with an database (US National Library of Medicine) for urticant.